Quick Answer
Acrivon Therapeutics, Inc. reported Diluted EPS of $2.02 per share (loss) for fiscal year 2025.
Acrivon Therapeutics, Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$2.02 | +15.1% |
| 2024 | -$2.38 | +13.1% |
| 2023 | -$2.74 | +63.8% |
| 2022 | -$7.56 | +18.9% |
| 2021 | -$9.32 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$0.47 | +20.3% | +14.5% |
| June 30, 2025 | -$0.55 | -5.8% | -7.8% |
| March 31, 2025 | -$0.51 | +30.1% | +13.6% |
| September 30, 2024 | -$0.59 | +10.6% | -13.5% |
| June 30, 2024 | -$0.52 | +17.5% | +28.8% |
| March 31, 2024 | -$0.73 | -25.9% | -10.6% |
| September 30, 2023 | -$0.66 | +87.2% | -4.8% |
| June 30, 2023 | -$0.63 | +80.9% | -8.6% |
- Acrivon Therapeutics, Inc. showed an increase of +15.1% in Diluted EPS compared to the prior fiscal year.
- Over the 2021–2025 period, Acrivon Therapeutics, Inc.’s diluted eps has grown by 78.3% (from $9.32 per share (loss) to $2.02 per share (loss)).
- The most recent figure is from Acrivon Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 19, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: